Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation
Status:
Terminated
Trial end date:
2021-03-13
Target enrollment:
Participant gender:
Summary
Grazoprevir/elbasvir combination therapy is highly effective in the treatment of genotype 1b
chronic hepatitis C, and the drug-drug interaction with central immunosuppressant, such as
tacrolimus, should be manageable. The aim of this study is to assess the efficacy and
tolerability of grazoprevir/elbasvir combination therapy in treating genotype 1b chronic
hepatitis C after liver or kidney transplantation.